Highlights Femasys Inc.

Equities

FEMY

US31447E1055

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
1.33 ^USD	-3.62%		-4.32%	+36.41%

09/05	Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/05	Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140	09/05	MT
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility	20/03	CI
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	06/03	CI
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women	26/01	CI
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah	23/01	CI
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine	15/12	CI
Femasys Inc. Completes Enrollment of Femaseed Pivotal Trial in Support of Commercial Launch	30/11	CI
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186	14/11	MT
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation	26/23/26	CI
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate	27/23/27	CI
Femasys Gets US FDA Approval to Market Infertility Treatment Procedure FemaSeed; Shares Rise After Hours	26/23/26	MT
Femasys Gets License to Sell Products Directly in Canada	31/23/31	MT
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Earnings Flash (FEMY) FEMASYS Reports Q2 Revenue $320,514	10/23/10	MT
Femasys Inc. Initiates Enrollment in Pivotal Trial of Its Permanent Birth Control Candidate FemBloc	03/23/03	CI
Femasys Gets Notice of Allowance for Female Permanent Birth Control Product Candidate; Stock Surges	27/23/27	MT
Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women	26/23/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Femasys Inc.

Equities

FEMY

US31447E1055

Highlights

Filters